Some of our brightest, most innovative thinkers are at start-up companies. But these companies often have a hard time raising capital. Venture-capital firms have become more cautious, unwilling to fund start-ups that have bright ideas but whose products are a long way from commercial viability. Venture capitalists consider such start-ups—such as early-stage biotech firms—too risky to justify their investment.
To read the full, original article click on this link: Robert Pozen: Why Not Venture-Capital Philanthropy? - WSJ.com
